Siemens Healthineers AG

Siemens Healthineers AG

SMMNY - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$51.94B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Siemens Healthineers AGSiemens Healthineers AG22.22.28%11%2.3-

Earnings Call Q4 2026

November 5, 2026 - AI Summary

Strong FY26 performance + solid equipment momentum (good) - Synergetic Core: +8.1% YoY in Q4, leading to +6.1% for FY26; backed by healthy demand across geographies. - Book-to-bill: 1.15 in Q4 and 1.14 for FY26 (equipment demand strength). - Group revenue: +5.9% YoY in Q4. - Clinical/portfolio proof point: Quest Diagnostics contract extended by 5 years—supports confidence in Atellica platform and Core Lab industrialization.
Diagnostics situation: sequential stabilization but ongoing YoY pressure + margins helped by one-offs (mixed/bad) - Diagnostics revenue: stabilized sequentially, but still -4.2% YoY in Q4. - Margin trend: sequential margin improved (mid-single digit levels) but FY26 remains pressured YoY, partly from commercial normalization and China. - China: group revenue -2% in Q4; Diagnostics in China continues to decline due to structural market rebasing, while Synergetic Core grows on low/stable levels.
FY27 outlook: revenue growth 4–5%, EPS 2.20–2.40 (forecast) - Comparable revenue growth (FY27): +4% to +5%. - Includes ~-0.7% growth dilution from partial exit of general imaging ultrasound. - Includes a more prudent China assumption (especially Synergetic Core). - Adjusted EPS (FY27): EUR 2.20 to EUR 2.40. - Underlying narrative: double-digit underlying earnings growth, with tariffs-related mitigation from 2026 actions, but offset by inflation and separation-related impacts.

Exclusive for Stockcircle Pro members

Sign upSign Up
$10.29

Current Fair Value

55.8% downside

Overvalued by 55.8% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$51.94 Billion
Enterprise Value$49.92 Billion
Annual dividend$0.59
Dividend yield2.28%
Earnings per Share$1
Beta0.83
Outstanding Shares2,230,000,000

Return

Return on Equity11.17%ROE
Return on Assets4.75%
Return on Invested Capital9.80%

Valuation & Multiples

P/E Ratio22.2P/E Ratio
PEG5527.05PEG
Price to Sales2.33Price to Sales
Price to Book Ratio2.91Price to Book Ratio
Enterprise Value to Revenue2.11
Enterprise Value to EBIT15.22
Enterprise Value to Net Income22
Total Debt to Enterprise0.01
Debt to Equity0.03Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
November 5, 2026
EPS
$0.30
Est. $0.38
Revenue
$7.62 B
Est. $7.64 B

Next Earnings Call

Expected Date
February 4, 2027
EPS Estimate
$0.28
Consensus analyst estimate
Revenue Estimate
$6.56 B
Consensus analyst estimate

Institutional Sentiment (Put/Call)

No data available for the latest quarter.

Institutional Ownership

No data available for the latest quarter.

About Siemens Healthineers AG

74,000 employees
CEO: Bernhard Montag

Siemens Healthineers AG, operating through its various subsidiaries, is dedicated to the development, production, and worldwide distribution of a comprehensive portfolio of diagnostic and therapeutic solutions for healthcare professional...